Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Dec 4;2020(1):18-23.
doi: 10.1182/hematology.2020000160.

Treatment of relapsed chronic lymphocytic leukemia after venetoclax

Meghan C Thompson  1 , Anthony R Mato  1
Affiliations
Case Reports

Treatment of relapsed chronic lymphocytic leukemia after venetoclax

Meghan C Thompson et al. Hematology Am Soc Hematol Educ Program. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.R.M. has served as a consultant for Celgene, Acerta, and Janssen; has served as a consultant for and received research funding from AbbVie, Loxo, Genentech, Pharmacyclics, AstraZeneca, Sunesis, and Johnson & Johnson; has received research funding from DTRM Biopharma and Gilead; and has served as a consultant for, received research funding from, is a DSMB member, and other for TG Therapeutics. M.C.T. declares no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Algorithm for treatment of CLL after progression on venetoclax-based therapy.
See this image and copyright information in PMC

References

    1. Roberts AW, Davids MS, Pagel JM, et al. . Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311-322. - PMC - PubMed
    1. Seymour JF, Kipps TJ, Eichhorst B, et al. . Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120. - PubMed
    1. Fischer K, Al-Sawaf O, Bahlo J, et al. . Venetoclax and obinatuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236. - PubMed
    1. Kater AP, Seymour JF, Hillmen P, et al. . Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269-277. - PubMed
    1. Coutre S, Choi M, Furman RR, et al. . Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131(15):1704-1711. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts